Affiliation:
1. Ghost Lab, T Cell Memory and Tolerance Section, Laboratory of Cellular and Molecular Immunology, National Institutes of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
Abstract
Tumor-associated macrophages (TAM) promote tumor survival, angiogenesis, and metastases. Although they express MHC class II molecules, little is known about their ability to present tumor antigens to tumor-infiltrating CD4 T cells, and the consequences of such presentation. To answer these questions, we used a C57/BL10 mouse tumor model where we subcutaneously implant a bladder carcinoma cell line naturally expressing the H-Y male antigen into female mice, making the H-Y antigen a de facto neoantigen. We found that TAMs indeed present tumor antigens to effector CD4 T cells and that such presentation is necessary for tumor rejection. As a consequence of this interaction, TAMs are reeducated to produce lower amounts of tumor-promoting proteins and greater amounts of inflammatory proteins. The reeducation process of the TAMs is transcriptionally characterized by an IFNγ signature, including genes of known antiviral and antibacterial functions. CD4 production of IFNγ, and not TNFα or CD40L, is required for the reeducation process and tumor rejection. Furthermore, IFNγ signaling on antigen-presenting TAMs and not on bystander TAMs, is necessary for the antitumor effect. These data identify critical mechanisms of tumor rejection by CD4 T cells and underscores the importance of effector CD4 T cell–tissue macrophage interactions not only at the tumors site but potentially in other tissues.
Significance:
In the tumor microenvironment, TAMs are capable of presenting tumor antigens to effector CD4 T cells. Upon antigen recognition, the CD4 cells transform transcriptionally, phenotypically, and functionally the TAMs inducing tumor rejection. This reeducation process requires both cognate interaction and IFNγ signaling on the same macrophage.
Funder
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Publisher
American Association for Cancer Research (AACR)
Reference56 articles.
1. CD4 cells can be more efficient at tumor rejection than CD8 cells;Perez-Diez;Blood,2007
2. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer;Tran;Science,2014
3. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma;Veatch;J Clin Invest,2018
4. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer;Zacharakis;Nat Med,2018
5. The role of myeloid cells in the promotion of tumour angiogenesis;Murdoch;Nat Rev Cancer,2008
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献